非糖尿病人群HbA1c访视间变异性与主要不良心血管事件及全因死亡风险
在无糖尿病和心血管疾病的初级保健人群中,三次年度HbA1c均在正常范围内(<6.5% [48 mmol/mol])的6756人纳入分析,中位随访6.3年。HbA1c变异性每增加1个SD,主要不良心血管事件(MACE)风险显著升高(HRSD 1.09 [95% CI 1.03-1.15]),全因死亡风险也显著升高(HRSD 1.13 [95% CI 1.07-1.20]),但与2型糖尿病发病无显著关联(HRSD 1.00 [95% CI 0.95-1.05])。
要点
- 非糖尿病人群HbA1c访视间变异性高与MACE风险增加相关(HRSD 1.09)。
- HbA1c变异性高与全因死亡风险增加相关(HRSD 1.13)。
- HbA1c变异性与2型糖尿病发病无显著关联(HRSD 1.00)。
核心结论
- 在无糖尿病和心血管疾病的初级保健人群中,高HbA1c变异性与MACE和全因死亡风险增加相关,但与2型糖尿病发病无关。
研究设计与样本
- 回顾性队列研究,纳入无糖尿病或心血管疾病史且三次年度HbA1c均在正常范围(<6.5% [48 mmol/mol])的初级保健患者6756人。
- HbA1c变异性以三次HbA1c测量值线性回归残差的标准差表示,并从回归中获取估计指数HbA1c(截距)和时间趋势(斜率)。
- 随访从第三次测量日期开始,采用Cox回归分析,调整传统危险因素、截距和趋势,结果以变异性每增加1个SD的风险比(HRSD)报告。
主要发现
- 中位随访6.3年期间,996人发生MACE,856人死亡,1267人发生2型糖尿病。
- HbA1c变异性增加与MACE风险显著相关(HRSD 1.09 [95% CI 1.03-1.15])。
- HbA1c变异性增加与全因死亡风险显著相关(HRSD 1.13 [95% CI 1.07-1.20])。
- HbA1c变异性与2型糖尿病发病无显著关联(HRSD 1.00 [95% CI 0.95-1.05])。
- 计算了MACE和全因死亡的5年绝对风险,发现按年龄、性别、合并症和HbA1c变异性定义的多个亚组间存在临床相关差异。
临床怎么用
- 在无糖尿病人群中,关注HbA1c访视间变异性可能有助于识别MACE和全因死亡高风险个体。
- 对于HbA1c正常但变异性较高的个体,可考虑加强心血管风险因素评估与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to study whether visit-to-visit variability of glycated hemoglobin A1c (HbA1c) is associated with incident major adverse cardiovascular events (MACE), all-cause mortality, and type 2 diabetes in people without diabetes. RESEARCH DESIGN AND METHODS: We included primary care patients with no history of diabetes or cardiovascular disease and with three annual HbA1c measurements within normal range (<6.5% [48 mmol/mol]). For each individual, we measured the HbA1c variability as the SD of the residuals obtained from a linear regression on the three HbA1c measurements. From the linear regression, we also obtained the estimated index HbA1c (intercept) and the trend over time (slope). Follow-up began at the date of the third measurement. Associations between HbA1c variability and outcome were analyzed using Cox regression, adjusted for traditional risk factors, intercept, and trend and reported as hazard ratio per SD increase in variability (HRSD). RESULTS: In total, 6,756 individuals were included. During a median follow-up time of 6.3 years, 996 developed MACE, 856 died, and 1,267 developed type 2 diabetes. We found a significant association between increasing HbA1c variability and incident MACE (HRSD 1.09 [95% CI 1.03-1.15]) and all-cause mortality (HRSD 1.13 [95% CI 1.07-1.20]), whereas there were no associations with type 2 diabetes (HRSD 1.00 [95% CI 0.95-1.05]). We calculated 5-year absolute risks of MACE and all-cause mortality and found clinically relevant differences across several age, sex, comorbidity, and HbA1c variability-defined subgroups. CONCLUSIONS: In a primary care population free of diabetes and cardiovascular disease, high HbA1c variability was associated with increased risks of MACE and all-cause mortality.
引用
- Ghouse J, Skov MW, Kanters JK, et al. Visit-to-Visit Variability of Hemoglobin A1c in People Without Diabetes and Risk of Major Adverse Cardiovascular Events and All-Cause Mortality. Diabetes Care. 2018. PMID: 30352898. doi:10.2337/dc18-1396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。